Summary

The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.
Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.
“The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023.”
The market is analyzed across four key products: drugs, probiotics, prebiotics, and synbiotics. The segment with the biggest share in the Human Microbiome market in 2023 is Probiotics, Driven by increasing consumer awareness about the benefits of probiotics for gut health, immunity, and overall wellness. Still, the Prebiotics segment held the second-largest market share. Additionally, widespread consumer demand and acceptance as health supplements along with active research supporting health claims on probiotics supports the segment growth. The market is also propelled by the growing popularity of functional foods and beverages containing probiotics.
“The Asia Pacific region is growing at the highest CAGR in the human microbiome market from 2024 to 2030.”
The Asia Pacific is estimated to be the fastest-growing segment of the market primarily due to the increasing awareness of microbiome health, emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicine. The development of high – throughout sequencing technologies has made it possible to sequence the entire mircrobiome in a single sample, enabling researchers to more accurately and comprehensively characterize the microbial communities that are present in samples. Challenges in terms of data protection and privacy, as well as high cost of human mircrobiomes, are expected to restrain the growth of the Asia- pacific market. In addition, there may be cultural and linguistic barriers to adoption in certain region, as well as concerns about the accuracy and clinical utility of microbiome sequencing data.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Executives - 25%, CXOs - 30%, and Managers - 45%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa -5%..







List of Companies Profiled in the Report:
• Nestle S.A. (Switzerland)
• Ferring Pharmaceuticals (Switzerland)
• BiomeBank (Australia)
• Seed Health, Inc. (US)
• International Flavors & Fragrances Inc (US)
• Pendulum (US)
• BioHM Health Inc. (US)
• Actial Farmaceutica SRL (Italy)
• Optibiotix Health plc (UK)
• Resbiotic (US)
• Infinant Health Inc (US)
• Biogaia AB (Sweden)
• Exegi Pharma Llc (US)

Research Coverage:
This research report categorizes the Human Microbiome market by Product (Drugs, Probiotics, Prebiotics, and others), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Biotherapeutic Products, and Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the Human Microbiome market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Start-Ups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the Human Microbiome market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market
• Competitive Assessment: Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US) among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 30
1.3 STUDY SCOPE 30
1.3.1 MARKET SEGMENTATION 30
1.4 YEARS CONSIDERED 31
1.5 CURRENCY 31
1.6 RESEARCH LIMITATIONS 31
1.7 STAKEHOLDERS 31
1.8 SUMMARY OF CHANGES 32
1.9 IMPACT OF AI/GEN AI 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 35
2.2 MARKET ESTIMATION METHODOLOGY 36
2.2.1 MARKET ESTIMATION 36
2.2.1.1 Insights of primary experts 38
2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS 39
2.3 MARKET GROWTH RATE PROJECTIONS 40
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 42
2.5 RESEARCH ASSUMPTIONS 43
2.6 LIMITATIONS 43
2.7 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 48
4.1 HUMAN MICROBIOME MARKET OVERVIEW 48
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT AND COUNTRY (2023) 49
4.3 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2030) 49

5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
5.2.1 DRIVERS 51
5.2.1.1 Collaborative initiatives between organizations and academia in microbiome industry 51
5.2.1.2 Increasing number of start-ups/SMEs exploring microbiome niche 53
5.2.1.3 Advancements in microbiome sequencing 54
5.2.2 RESTRAINTS 54
5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes 54
5.2.2.2 High investments in commercialization of microbiome drugs 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 Increasing demand for personalized medicine 56
5.2.3.2 Emergence of postbiotics 57
5.2.4 CHALLENGES 57
5.2.4.1 Slow patient adoption of microbiome-based therapies 57
5.2.4.2 Complexities involved in development of microbiome therapies 58
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 58
5.4 PRICING ANALYSIS 59
5.4.1 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER 59
5.4.2 AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021–2023 60
5.4.3 AVERAGE SELLING PRICE ANALYSIS, BY REGION 61
5.5 PIPELINE ANALYSIS 62
5.6 PATENT ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 65
5.8 SUPPLY CHAIN ANALYSIS 66
5.9 VALUE CHAIN ANALYSIS 67
5.10 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 68
5.11 TECHNOLOGY ANALYSIS 70
5.11.1 KEY TECHNOLOGIES 70
5.11.1.1 Whole-genome sequencing 70
5.11.1.2 16s RNA sequencing method 71
5.11.1.3 Nanopore sequencing 71
5.11.2 COMPLEMENTARY TECHNOLOGIES 71
5.11.2.1 Metatranscriptomics 71
5.11.2.2 Metagenomics 72
5.11.2.3 Metabolomics 72
5.11.3 ADJACENT TECHNOLOGIES 73
5.11.3.1 Sample preparation 73
5.11.3.2 Data analysis 73
5.11.3.3 Library synthesis 73
5.12 KEY CONFERENCES & EVENTS IN 2024–2025 74
5.13 REGULATORY ANALYSIS 76
5.13.1 REGULATORY LANDSCAPE 76
5.13.1.1 North America 76
5.13.1.2 Europe 77
5.13.1.3 Asia Pacific 78
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
5.14 PORTER’S FIVE FORCES ANALYSIS 84
5.14.1 THREAT OF NEW ENTRANTS 85
5.14.2 THREAT OF SUBSTITUTES 85
5.14.3 BARGAINING POWER OF BUYERS 86
5.14.4 BARGAINING POWER OF SUPPLIERS 86
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 87
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
5.15.2 BUYING CRITERIA 88
5.16 CASE STUDY ANALYSIS 88
5.16.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION 88
5.16.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION 88
5.16.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS. 89
5.17 INVESTMENT & FUNDING SCENARIO 89
5.17.1 OTHER INVESTMENTS AND FUNDING 93
6 HUMAN MICROBIOME MARKET, BY PRODUCT 95
6.1 INTRODUCTION 96
6.2 DRUGS 96
6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET 96
6.3 PROBIOTICS 97
6.3.1 GROWING CONSUMER AWARENESS ABOUT PROBIOTICS FOR IMPROVED GUT HEALTH AND IMMUNITY TO AID MARKET GROWTH 97
6.4 PREBIOTICS 100
6.4.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH 100
6.5 SYNBIOTICS 103
6.5.1 GROWING DEMAND FOR PERSONALIZED TREATMENT AND RISING INCIDENCE OF DYSBIOSIS TO AUGMENT MARKET GROWTH 103

7 HUMAN MICROBIOME MARKET, BY DISEASE 106
7.1 INTRODUCTION 107
7.2 INFECTIOUS DISEASES 107
7.2.1 EMERGENCE OF MULTI-DRUG-RESISTANT BACTERIA TO BOOST MARKET GROWTH 107
7.3 GASTROINTESTINAL DISEASES 109
7.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO PROPEL MARKET GROWTH 109
7.4 ENDOCRINE & METABOLIC DISORDERS 111
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET GROWTH 111
7.5 OTHER DISEASES 115
8 HUMAN MICROBIOME MARKET, BY TYPE 118
8.1 INTRODUCTION 119
8.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 119
8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH 119
8.3 LIVE BIOTHERAPEUTIC PRODUCTS (LBP) 122
8.3.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET 122
8.4 OTHER MICROBIOME TYPES 125
9 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION 129
9.1 INTRODUCTION 130
9.2 ORAL ROUTE OF ADMINISTRATION 130
9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO DRIVE MARKET GROWTH 130
9.3 RECTAL ROUTE OF ADMINISTRATION 133
9.3.1 PRODUCT APPROVALS AND EFFICACY IN TARGETED DELIVERY TO SUPPORT MARKET GROWTH 133
10 HUMAN MICROBIOME MARKET, BY END USER 136
10.1 INTRODUCTION 137
10.2 HOSPITALS & CLINICS 137
10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH 137
10.3 LONG-TERM CARE FACILITIES 140
10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET 140
10.4 OTHER END USERS 143

11 HUMAN MICROBIOME MARKET, BY REGION 146
11.1 INTRODUCTION 147
11.2 NORTH AMERICA 147
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 150
11.2.2 US 151
11.2.2.1 Strong ecosystem backed by regulation, research,
and funding to drive market 151
11.2.3 CANADA 153
11.2.3.1 Government initiatives, independent organizations,
and academia collaborations to boost microbiome research 153
11.3 EUROPE 156
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 158
11.3.2 GERMANY 159
11.3.2.1 Rapid increase in government and private funding to propel market 159
11.3.3 UK 161
11.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth 161
11.3.4 FRANCE 163
11.3.4.1 Growing awareness and rise of specialized organizations
to boost growth 163
11.3.5 ITALY 166
11.3.5.1 Government intervention and academic institutions
to drive market growth 166
11.3.6 SPAIN 168
11.3.6.1 Growing academic research initiatives to boost growth 168
11.3.7 REST OF EUROPE 170
11.4 ASIA PACIFIC 172
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 175
11.4.2 CHINA 176
11.4.2.1 Increasing R&D investments to drive growth 176
11.4.3 JAPAN 178
11.4.3.1 Growing geriatric population to present opportunities
for market growth 178
11.4.4 INDIA 181
11.4.4.1 Increasing prevalence of chronic diseases to support growth 181
11.4.5 SOUTH KOREA 183
11.4.5.1 Increasing prevalence of chronic diseases to support growth 183
11.4.6 AUSTRALIA 185
11.4.6.1 Growing number of product approvals to boost growth 185
11.4.7 REST OF ASIA PACIFIC 187

11.5 LATIN AMERICA 189
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 191
11.5.2 BRAZIL 192
11.5.2.1 Rising probiotics demand to drive market 192
11.5.3 REST OF LATIN AMERICA 194
11.6 MIDDLE EAST 196
11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 198
11.6.2 GCC COUNTRIES 199
11.6.2.1 Saudi Arabia 201
11.6.2.1.1 Increasing focus on R&D to boost market growth 201
11.6.2.2 UAE 203
11.6.2.2.1 Increasing focus on R&D and healthcare spending to boost market growth 203
11.6.2.3 Rest of GCC countries 205
11.6.3 REST OF MIDDLE EAST 207
11.7 AFRICA 209
11.7.1 STUDIES AND INITIATIVES TO BOOST MARKET GROWTH 209
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 211
12 COMPETITIVE LANDSCAPE 213
12.1 INTRODUCTION 213
12.1.1 KEY PLAYER STRATEGY/RIGHT TO WIN 213
12.1.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
IN HUMAN MICROBIOME MARKET 213
12.2 REVENUE ANALYSIS, 2021–2023 215
12.3 MARKET SHARE ANALYSIS, 2023 217
12.4 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 220
12.4.1 STARS 220
12.4.2 EMERGING LEADERS 220
12.4.3 PERVASIVE PLAYERS 220
12.4.4 PARTICIPANTS 220
12.4.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 222
12.4.5.1 Company footprint 222
12.4.5.2 Product footprint 223
12.4.5.3 Type footprint 224
12.4.5.4 Disease footprint 225
12.4.5.5 Region footprint 226
12.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 226
12.5.1 PROGRESSIVE COMPANIES 226
12.5.2 RESPONSIVE COMPANIES 226
12.5.3 DYNAMIC COMPANIES 227
12.5.4 STARTING BLOCKS 227
12.5.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 228
12.6 COMPANY VALUATION & FINANCIAL METRICS 230
12.7 BRAND/PRODUCT COMPARISON 231
12.8 COMPETITIVE SCENARIO 233
12.8.1 PRODUCT APPROVALS 233
12.8.2 DEALS 234
13 COMPANY PROFILES 235
13.1 KEY PLAYERS 235
13.1.1 INTERNATIONAL FLAVORS & FRAGRANCES, INC. 235
13.1.1.1 Business overview 235
13.1.1.2 Products offered 236
13.1.1.3 Recent developments 238
13.1.1.3.1 Deals 238
13.1.1.4 MnM view 239
13.1.1.4.1 Key strengths 239
13.1.1.4.2 Strategic choices 239
13.1.1.4.3 Weaknesses & competitive threats 239
13.1.2 SEED HEALTH, INC. 240
13.1.2.1 Business overview 240
13.1.2.2 Products offered 240
13.1.2.3 Recent developments 241
13.1.2.3.1 Deals 241
13.1.2.4 MnM view 242
13.1.2.4.1 Key strengths 242
13.1.2.4.2 Strategic choices 242
13.1.2.4.3 Weaknesses & competitive threats 242
13.1.3 PENDULUM 243
13.1.3.1 Business overview 243
13.1.3.2 Products offered 244
13.1.3.3 Recent developments 244
13.1.3.3.1 Deals 244
13.1.3.4 MnM view 245
13.1.3.4.1 Key strengths 245
13.1.3.4.2 Strategic choices 245
13.1.3.4.3 Weaknesses & competitive threats 245
13.1.4 SERES THERAPEUTICS 246
13.1.4.1 Business overview 246
13.1.4.2 Products offered 247
13.1.4.3 Recent developments 247
13.1.4.3.1 Product approvals 247
13.1.4.3.2 Deals 248

13.1.4.4 MnM view 249
13.1.4.4.1 Key strengths 249
13.1.4.4.2 Strategic choices 249
13.1.4.4.3 Weaknesses & competitive threats 249
13.1.5 FERRING PHARMACEUTICALS 250
13.1.5.1 Business overview 250
13.1.5.2 Products offered 251
13.1.5.3 Recent developments 252
13.1.5.3.1 Product approvals 252
13.1.5.3.2 Deals 252
13.1.5.4 MnM view 253
13.1.5.4.1 Key strengths 253
13.1.5.4.2 Strategic choices 253
13.1.5.4.3 Weaknesses & competitive threats 253
13.1.6 BIOMEBANK 254
13.1.6.1 Business overview 254
13.1.6.2 Products offered 254
13.1.6.3 Recent developments 255
13.1.6.3.1 Product approvals 255
13.1.6.3.2 Expansions 255
13.1.7 BIOHM HEALTH INC. 256
13.1.7.1 Business overview 256
13.1.7.2 Products offered 256
13.1.7.3 Recent developments 258
13.1.7.3.1 Deals 258
13.1.8 ACTIAL FARMACEUTICA SRL 259
13.1.8.1 Business overview 259
13.1.8.2 Products offered 259
13.1.9 OPTIBIOTIX HEALTH PLC 260
13.1.9.1 Business overview 260
13.1.9.2 Products offered 261
13.1.9.3 Recent developments 262
13.1.9.3.1 Product approvals 262
13.1.9.3.2 Deals 262
13.1.10 RESBIOTIC 263
13.1.10.1 Business overview 263
13.1.10.2 Products offered 263
13.1.10.3 Recent developments 264
13.1.10.3.1 Expansions 264

13.1.11 INFINANT HEALTH INC. 265
13.1.11.1 Business overview 265
13.1.11.2 Products offered 265
13.1.12 BIOGAIA AB 266
13.1.12.1 Business overview 266
13.1.12.2 Products offered 268
13.1.12.3 Recent developments 269
13.1.12.3.1 Deals 269
13.1.12.3.2 Expansions 269
13.1.13 EXEGI PHARMA, LLC 270
13.1.13.1 Business overview 270
13.1.13.2 Products offered 270
13.1.13.3 Recent developments 271
13.1.13.3.1 Deals 271
13.2 OTHER PLAYERS 272
13.2.1 AOBIOME 272
13.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD. 273
13.2.3 NUBIYOTA 274
13.2.4 OXTHERA AB 275
13.2.5 NEXBIOME 276
13.2.6 VEDANTA BIOSCIENCES, INC. 277
13.2.7 ENTEROME 278
13.2.8 APSEN FARMACÊUTICA S.A. 279
13.2.9 METAGEN THERAPEUTICS, INC. 280
13.2.10 SNIPR BIOME 281
13.2.11 MAAT PHARMA SA 282
13.2.12 MIKROBIOMIK 283
14 APPENDIX 284
14.1 DISCUSSION GUIDE 284
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 287
14.3 CUSTOMIZATION OPTIONS 289
14.4 RELATED REPORTS 289
14.5 AUTHOR DETAILS 290